These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24975794)

  • 1. [Treatment of non-neurogenic masculine urinary incontinence due to overactive bladder: a review by the LUTS committee of the French Urological Association].
    Lebdai S; Haillot O; Azzouzi AR; Benchikh A; Campeggi A; Cornu JN; Delongchamps NB; Dumonceau O; Faix A; Fourmarier M; Lukacs B; Mathieu R; Misrai V; Robert G; de La Taille A; Descazeaud A
    Prog Urol; 2014 Jul; 24(9):588-94. PubMed ID: 24975794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
    Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T
    Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
    Henriet B; Roumeguère T
    Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.
    Everaert K; Gruenenfelder J; Schulte-Baukloh H; Egerdie RB; Khalaf K; Joshi M; Ni Q; Sussman D
    Int J Urol; 2015 Dec; 22(12):1131-7. PubMed ID: 26391359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis.
    López Ramos H; Torres Castellanos L; Ponce Esparza I; Jaramillo A; Rodríguez A; Moreno Bencardino C
    Urology; 2017 Feb; 100():53-58. PubMed ID: 27789302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
    Jo JK; Kim KN; Kim DW; Kim YT; Kim JY; Kim JY
    World J Urol; 2018 Feb; 36(2):305-317. PubMed ID: 29124347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.
    Sun Y; Luo D; Tang C; Yang L; Shen H
    Int Urol Nephrol; 2015 Nov; 47(11):1779-88. PubMed ID: 26433883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
    JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Schulte-Baukloh H; Bauer R; Jost W; Wissel J; van Ophoven A
    Fortschr Neurol Psychiatr; 2019 Feb; 87(1):23-30. PubMed ID: 30508871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
    Ginsberg DA; Drake MJ; Kaufmann A; Radomski S; Gousse AE; Chermansky CJ; Magyar A; Nicandro JP; Nitti VW;
    J Urol; 2017 Oct; 198(4):897-904. PubMed ID: 28536084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary incontinence in women.
    Wood LN; Anger JT
    BMJ; 2014 Sep; 349():g4531. PubMed ID: 25225003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.
    Habashy D; Losco G; Tse V; Collins R; Chan L
    BJU Int; 2015 Oct; 116 Suppl 3():61-5. PubMed ID: 26176660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
    Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
    Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.
    Chermansky CJ; Richter HE; Jacoby K; Titanji W; Jenkins B; Geib T; Brucker BM
    J Urol; 2022 Oct; 208(4):855-862. PubMed ID: 35830550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.